Patient Perspectives Regarding Allogeneic Bone Marrow Transplantation in Myelofibrosis

Jeanne Palmer, Robyn Scherber, Marlene Girardo, Holly Geyer, Heidi Kosiorek, Amylou Dueck, Tania Jain, Ruben Mesa

Research output: Contribution to journalArticle

Abstract

Hematopoietic stem cell transplantation (HCT) is a curative treatment for patients with myelofibrosis (MF); however, many HCT-eligible patients decline this potentially life-saving procedure. The reasons behind this decision are not clear. We sought to survey patients with MF to understand their perspective on HCT. A 63-question survey was posted on myeloproliferative neoplasm patient advocacy websites. A total of 129 patients with MF responded to the survey. Among these patients, 49 (41%) were referred for HCT, and 41(32%) attended the transplantation consult. Of the patients who attended the transplantation consult, 24 (59%) did not plan on going on to HCT, and 16 (41%) intended to proceed with HCT. Reasons for the decision to not undergo transplantation included the desire to not be ill, desire to not spend time in the hospital, and concerns about overall quality of life. Specifically, concerns related to financial impact and the risk of graft-versus-host disease (GVHD) were expressed. Patients who decided to proceed with HCT felt that this would extend their survival and allow them to be around family for longer. This is the first survey to investigate patient perceptions regarding HCT for MF. Less than one-half of the patients were referred for HCT, and of those, less than one-half planned on proceeding with the transplantation, suggesting that many patients do not receive this life-saving procedure. Further exploration of the basis of patients’ reluctance to proceed with HCT is warranted.

Original languageEnglish (US)
JournalBiology of Blood and Marrow Transplantation
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Primary Myelofibrosis
Homologous Transplantation
Hematopoietic Stem Cell Transplantation
Bone Marrow Transplantation
Transplantation
Patient Advocacy
Graft vs Host Disease
Quality of Life

Keywords

  • Bone marrow transplantation
  • Myelofibrosis
  • Patient perspective
  • Quality of life
  • Survey

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Patient Perspectives Regarding Allogeneic Bone Marrow Transplantation in Myelofibrosis. / Palmer, Jeanne; Scherber, Robyn; Girardo, Marlene; Geyer, Holly; Kosiorek, Heidi; Dueck, Amylou; Jain, Tania; Mesa, Ruben.

In: Biology of Blood and Marrow Transplantation, 01.01.2018.

Research output: Contribution to journalArticle

Palmer, Jeanne ; Scherber, Robyn ; Girardo, Marlene ; Geyer, Holly ; Kosiorek, Heidi ; Dueck, Amylou ; Jain, Tania ; Mesa, Ruben. / Patient Perspectives Regarding Allogeneic Bone Marrow Transplantation in Myelofibrosis. In: Biology of Blood and Marrow Transplantation. 2018.
@article{7235d4cd4e8a4d09832df0c63d4c4bd4,
title = "Patient Perspectives Regarding Allogeneic Bone Marrow Transplantation in Myelofibrosis",
abstract = "Hematopoietic stem cell transplantation (HCT) is a curative treatment for patients with myelofibrosis (MF); however, many HCT-eligible patients decline this potentially life-saving procedure. The reasons behind this decision are not clear. We sought to survey patients with MF to understand their perspective on HCT. A 63-question survey was posted on myeloproliferative neoplasm patient advocacy websites. A total of 129 patients with MF responded to the survey. Among these patients, 49 (41{\%}) were referred for HCT, and 41(32{\%}) attended the transplantation consult. Of the patients who attended the transplantation consult, 24 (59{\%}) did not plan on going on to HCT, and 16 (41{\%}) intended to proceed with HCT. Reasons for the decision to not undergo transplantation included the desire to not be ill, desire to not spend time in the hospital, and concerns about overall quality of life. Specifically, concerns related to financial impact and the risk of graft-versus-host disease (GVHD) were expressed. Patients who decided to proceed with HCT felt that this would extend their survival and allow them to be around family for longer. This is the first survey to investigate patient perceptions regarding HCT for MF. Less than one-half of the patients were referred for HCT, and of those, less than one-half planned on proceeding with the transplantation, suggesting that many patients do not receive this life-saving procedure. Further exploration of the basis of patients’ reluctance to proceed with HCT is warranted.",
keywords = "Bone marrow transplantation, Myelofibrosis, Patient perspective, Quality of life, Survey",
author = "Jeanne Palmer and Robyn Scherber and Marlene Girardo and Holly Geyer and Heidi Kosiorek and Amylou Dueck and Tania Jain and Ruben Mesa",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.bbmt.2018.09.033",
language = "English (US)",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Patient Perspectives Regarding Allogeneic Bone Marrow Transplantation in Myelofibrosis

AU - Palmer, Jeanne

AU - Scherber, Robyn

AU - Girardo, Marlene

AU - Geyer, Holly

AU - Kosiorek, Heidi

AU - Dueck, Amylou

AU - Jain, Tania

AU - Mesa, Ruben

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Hematopoietic stem cell transplantation (HCT) is a curative treatment for patients with myelofibrosis (MF); however, many HCT-eligible patients decline this potentially life-saving procedure. The reasons behind this decision are not clear. We sought to survey patients with MF to understand their perspective on HCT. A 63-question survey was posted on myeloproliferative neoplasm patient advocacy websites. A total of 129 patients with MF responded to the survey. Among these patients, 49 (41%) were referred for HCT, and 41(32%) attended the transplantation consult. Of the patients who attended the transplantation consult, 24 (59%) did not plan on going on to HCT, and 16 (41%) intended to proceed with HCT. Reasons for the decision to not undergo transplantation included the desire to not be ill, desire to not spend time in the hospital, and concerns about overall quality of life. Specifically, concerns related to financial impact and the risk of graft-versus-host disease (GVHD) were expressed. Patients who decided to proceed with HCT felt that this would extend their survival and allow them to be around family for longer. This is the first survey to investigate patient perceptions regarding HCT for MF. Less than one-half of the patients were referred for HCT, and of those, less than one-half planned on proceeding with the transplantation, suggesting that many patients do not receive this life-saving procedure. Further exploration of the basis of patients’ reluctance to proceed with HCT is warranted.

AB - Hematopoietic stem cell transplantation (HCT) is a curative treatment for patients with myelofibrosis (MF); however, many HCT-eligible patients decline this potentially life-saving procedure. The reasons behind this decision are not clear. We sought to survey patients with MF to understand their perspective on HCT. A 63-question survey was posted on myeloproliferative neoplasm patient advocacy websites. A total of 129 patients with MF responded to the survey. Among these patients, 49 (41%) were referred for HCT, and 41(32%) attended the transplantation consult. Of the patients who attended the transplantation consult, 24 (59%) did not plan on going on to HCT, and 16 (41%) intended to proceed with HCT. Reasons for the decision to not undergo transplantation included the desire to not be ill, desire to not spend time in the hospital, and concerns about overall quality of life. Specifically, concerns related to financial impact and the risk of graft-versus-host disease (GVHD) were expressed. Patients who decided to proceed with HCT felt that this would extend their survival and allow them to be around family for longer. This is the first survey to investigate patient perceptions regarding HCT for MF. Less than one-half of the patients were referred for HCT, and of those, less than one-half planned on proceeding with the transplantation, suggesting that many patients do not receive this life-saving procedure. Further exploration of the basis of patients’ reluctance to proceed with HCT is warranted.

KW - Bone marrow transplantation

KW - Myelofibrosis

KW - Patient perspective

KW - Quality of life

KW - Survey

UR - http://www.scopus.com/inward/record.url?scp=85056309710&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056309710&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2018.09.033

DO - 10.1016/j.bbmt.2018.09.033

M3 - Article

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

ER -